Main contents starts here
Press Releases 2005
- December 26, 2005
House Foods and Takeda To Form Business Alliance
Transfer of the Business of Takeda's Wholly Owned Subsidiary, Takeda Food Products to A New Joint Venture with House Foods - December 21, 2005
TAP LICENSES PREVACID® INTELLECTUAL PROPERTY RIGHTS TO NOVARTIS FOR OTC DEVELOPMENT AND FUTURE COMMERCIALIZATION
− Agreement Part of TAP's Strategy to Maintain Its Leadershipin Area of Gastroenterological Products − - November 17, 2005
New Data Shows Takeda's Actos® (pioglitazone HCl) Reduced Heart Attacks by 28 Percent in People with Type 2 Diabetes
PROactive Study also showed a 37 percent reduction in acute coronary syndrome with ACTOS - November 2, 2005
Takeda and Pronova Biocare to Agree an License and Supply Agreement on Omacor®, Treatment for Hypertriglyceridemia - November 1, 2005
ACTOplus met™ (pioglitazone HCl and metformin HCl) Now Available in U.S. Pharmacies
New product combines two widely used diabetes medications in a single tablet, offering patients a convenient option - October 12, 2005
Risk of heart attack and cardiovascular death significantly reduced by Candesartan therapy in patients with heart failure - October 11, 2005
Additional Indication of Blopress® for the Treatment of Chronic Heart Failure Approved in Japan - October 3, 2005
Hitachi and Takeda to Establish a Joint Venture for Information System Support for Takeda - September 29, 2005
Takeda to Co-Develop and Co-Promote an Investigational Compound for the Treatment of Cancer with Merck KGaA - September 26, 2005
ROZEREM™ (ramelteon) Now Available in U.S. Pharmacies
First and only non-scheduled prescription sleep medication - September 13, 2005
"PROactive" STUDY SHOWS TAKEDA'S ACTOS®(pioglitazone HCl) REDUCES HEART ATTACKS, STROKES AND DEATHS IN PATIENTS WITH TYPE 2 DIABETES - August 30, 2005
TAP Advances Takeda's Investigational Gastroenterology Compound TAK-390MR into Phase III Clinical Studies
TAP to Lead Clinical Development Program and Commercialization - August 30, 2005
Actoplus Met™(pioglitazone HCl and metformin HCl) Approvedby the U.S. FDA for Type 2 Diabetes - August 19, 2005
Takeda Obtained Approval of an Additional Indication of Premenopausal Breast Cancer for Leuplin® SR for Injection Kit 11.25 - August 3, 2005
Santhera and Takeda Establish Collaboration to Develop and Market Idebenone (SNT-MC17) in Neuromuscular Disease
Idebenone (SNT-MC17) Will Be the First Treatment for Friedreich’s Ataxia - July 27, 2005
Takeda's Investigational Compound (TAK-242) for Severe Sepsis Designated as Fast Track Drugs from the U.S. FDA - July 23, 2005
Takeda Receives Approval from the Food and Drug Administration for ROZEREM™ (ramelteon) - July 14, 2005
Takeda Acquires the Rights to DPP4 Inhibitors Granted to PPD - July 6, 2005
Candesartan therapy can reduce the risk of diabetes in heart failure patients11
Candesartan is the first angiotensin receptor blocker (ARB) shown to reduce the risk of diabetes in heart failure patients compared to placebo, in new study analysis1 - July 4, 2005
Takeda to Disclose Information on Clinical Trials in the Web site - June 30, 2005
Takeda Submits New Drug Application for Combination Type 2 Diabetes Medication Containing Pioglitazone HCl and Glimepiride - June 30, 2005
Paradigm and Takeda Enter Into CNS Therapeutic Area Alliance - June 28, 2005
Transfer of Shares of Takeda Schering-Plough Animal Health K.K. from Takeda to Schering-Plough - June 3, 2005
Heart failure patients perceive improvement in symptoms on Candesartan treatment1
Data showing Candesartan improves patients' perception of symptoms reinforces existing CHARM study data regarding physician-reported functional status improvements - May 30, 2005
DIRECT − the first large-scale international clinical programme for the treatment of diabetic retinopathy
Baseline data published from landmark DIRECT*1 trial Programme which evaluates the role of candesartan cilexetilin reducing the onset and progression of diabetic retinopathy,the most feared complication of diabetes*2 - May 20, 2005
FDA Approves Candesartan Cilexetil for Use with an ACE Inhibitor in the Treatment of Heart Failure
Candesartan is the only ARB proven to provide benefits when added to conventional heart failure therapy, including ACE inhibitors plus beta blockers - April 7, 2005
Toray and Takeda to Jointly Develop and Marketan Investigational Compound for Frequent Urination/Urinary Incontinence - April 7, 2005
Partial Transfer of Wyeth K.K. Equity from Takeda to Wyeth - March 30, 2005
Sucampo Submits New Drug Application for Lubiprostone, an Investigational Compound for the Treatment of Chronic Idiopathic Constipation
Submission Marks Key Step in Takeda and Sucampo Partnership in U.S. Market - March 30, 2005
Takeda to Transfer its Life-environmental Business to Osaka Gas - March 30, 2005
Discontinuation of Development of Anti-Diabetic Agent TAK-559 - March 29, 2005
Announcing Launch of ENBREL,Treatment of Rheumatoid Arthritis - March 1, 2005
3M Pharmaceuticals and Takeda to Collaborate on Potential Treatment for Cervical High-Risk HPV Infection and Cervical Dysplasia - February 25, 2005
FDA Approves Candesartan Cilexetil for the Treatment of Heart Failure - February 7, 2005
Takeda to Acquire Syrrx - February 4, 2005
Takeda to Support Relief Effort for Tsunami and Earthquake Disaster in Southeast Asia
All Takeda employees in the world express their deepest sympathy and condolences to all those affected by this disaster. - January 25, 2005
ENBREL® to Treat Rheumatoid Arthritis Approved